-+ 0.00%
-+ 0.00%
-+ 0.00%

Serina Therapeutics Q2 FY26 net loss narrows to $6.36 million; revenue falls to no grant revenue

PUBT·08/13/2026 20:05:54
Listen to the news
Serina Therapeutics Q2 FY26 net loss narrows to $6.36 million; revenue falls to no grant revenue
  • Serina Therapeutics posted a net loss of USD 6.36 million in the quarter ended June 30, 2026, narrowing from USD 6.46 million.
  • Operating loss widened to USD 6.78 million as operating expenses climbed to USD 6.78 million from USD 5.7 million.
  • Research and development costs rose to USD 3.82 million from USD 3.15 million, driven by higher clinical activity and headcount.
  • General and administrative expense increased to USD 2.97 million from USD 2.54 million on higher legal spending tied to patent and financing.
  • Cash and cash equivalents totaled USD 23 million at June 30, 2026; management flagged substantial doubt about going concern without additional financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-26-000047), on August 13, 2026, and is solely responsible for the information contained therein.